Breathtaking AI advances necessitate a new suite of brain science-inspired policies to build brain capital.

There is a growing global movement among economic, public policy and academic communities questioning the appropriateness of gross domestic product (GDP), and specifically its growth, as an indicator of progress. Despite the broad range of indices and dashboards that have been developed to challenge it, GDP remains entrenched as the essential indicator of national prosperity, despite its purpose being to measure the size and performance of the economy.

Brain diseases have profound impacts on our health, our communities and the economy. In this brief, fellow Harris A. Eyre explains why Texas needs to establish a state research institute to tackle a growing brain health crisis.

Abstract

Scholars began reporting about this marketplace in the mid-2000s; however, there is no sign of it dissipating…

Vaccination policies are a cornerstone of public health, but anti-vaccine activists have been adamantly pushing for legislation that would weaken and dismantle the public health infrastructure, the authors write. In this issue brief, they examine vaccine policy challenges leading up to and during the COVID-19 pandemic, as well as the future of vaccine legislation in Texas and the United States.

The authors identify key themes that emerged from anti-vaccine testimonies during the 2021 Texas legislative session and consider the implications of these discussions as the next legislative session draws near.

Stem cells have two unique properties that make them an appealing therapeutic tool for regenerative medicine: they can grow indefinitely and can differentiate into a wide variety of cell types, including those that form blood, bones, lungs, skin, and the brain.

Scientists and members of the public exploring the controversial area of U.S. human embryo and embryoid research will find a complex and sometimes bewildering assortment of federal and state laws. The authors recommend additional guidance, but note slow progress in the development of embryo research policy.

Companies developing stem cell-based interventions should work with policymakers and patient advocates to address risks for current and future patients and to protect clinical research and the reputation of the field, write the authors. Read their full article in Cell & Gene Therapy Insights (free registration).